trending Market Intelligence /marketintelligence/en/news-insights/trending/hCAqbQZYxFt0MUCfHp38-A2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

TaiMed HIV-1 drug manufacturing facility clears US FDA pre-license inspection

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

TaiMed HIV-1 drug manufacturing facility clears US FDA pre-license inspection

The U.S. Food and Drug Administration completed the pre-license inspection of the WuXi Biologics Inc. facility, where TaiMed Biologics Inc.'s ibalizumab will be manufactured.

The regulator carried out the inspection from July 17 to Aug. 2 and made some observations that are not expected to impact the review timelines of the ibalizumab biologics license application.

Theratechnologies Inc. recently secured the commercial rights to ibalizumab in Israel, Norway, Russia, Switzerland and the EU. The company already owns the rights to the HIV-1 drug in the U.S. and Canada.

TaiMed Biologics said that WuXi Biologics, which is an affiliate of China-based WuXi AppTec, said it was committed to complete all follow-up actions as soon as possible.